We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
+6.3%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$183M
AUM Growth
-$3.29M
Cap. Flow
-$8.67M
Cap. Flow %
-4.73%
Top 10 Hldgs %
62.72%
Holding
56
New
18
Increased
15
Reduced
7
Closed
16

Top Buys

Rank Stock Value
1
TNET icon
TriNet
TNET
+$5.38M
2
OPCH icon
Option Care Health
OPCH
+$4.81M
3
MGTX icon
MeiraGTx Holdings
MGTX
+$3.64M
4
NTLA icon
Intellia Therapeutics
NTLA
+$3.43M
5
HCAT icon
Health Catalyst
HCAT
+$3.36M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$17.7M
2
CRL icon
Charles River Laboratories
CRL
+$6.54M
3
THC icon
Tenet Healthcare
THC
+$5.26M
4
JNJ icon
Johnson & Johnson
JNJ
+$5.18M
5
ALKS icon
Alkermes
ALKS
+$3.84M

Sector Composition

Rank Sector Weight
1 Healthcare 93.56%
2 Industrials 2.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
26
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$1.78M 0.97%
+40,000
New +$1.68M
SGEN
27
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$1.54M 0.84%
+12,000
New +$1.55M
LFST icon
28
Lifestance Health
LFST
$4.16B
$1.43M 0.78%
+289,335
New +$1.79M
BCRX icon
29
BioCryst Pharmaceuticals
BCRX
$2.37B
$1.34M 0.73%
116,732
+2,932
+3% +$36.6K
FLNA
30
PUT
Filana Therapeutics
FLNA
$43M
$1.21M 0.66%
40,900
+5,000
+14% +$180K
MORF
31
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1.15M 0.63%
+42,949
New +$1.17M
ELUT icon
32
Elutia
ELUT
$41.1M
$786K 0.43%
+185,014
New +$1.16M
BMEA icon
33
Biomea Fusion
BMEA
$90.4M
$690K 0.38%
+81,907
New +$699K
BBIO icon
34
BridgeBio Pharma
BBIO
$16.5B
$678K 0.37%
+89,027
New +$852K
RCKT icon
35
Rocket Pharmaceuticals
RCKT
$348M
$630K 0.34%
32,193
-167,807
-84% -$3.09M
GOSS icon
36
Gossamer Bio
GOSS
$66.5M
$575K 0.31%
+265,000
New +$2.18M
EOLS icon
37
Evolus
EOLS
$394M
$499K 0.27%
66,438
-93,762
-59% -$726K
TOI icon
38
The Oncology Institute
TOI
$498M
$455K 0.25%
+275,561
New +$773K
TNYA icon
39
Tenaya Therapeutics
TNYA
$168M
$215K 0.12%
+107,063
New +$261K
PSNL icon
40
Personalis
PSNL
$1.26B
$116K 0.06%
+58,668
New +$148K
ARDX icon
41
Ardelyx
ARDX
$1.24B
– –
-1,126,127
Closed -$1.34M
AVTR icon
42
Avantor
AVTR
$7.81B
– –
-122,668
Closed -$2.4M
BAX icon
43
Baxter International
BAX
$11.6B
– –
-39,000
Closed -$2.1M
CRL icon
44
Charles River Laboratories
CRL
$10.9B
– –
-33,220
Closed -$6.54M
INCY icon
45
Incyte
INCY
$23.5B
– –
-40,450
Closed -$2.7M
JNJ icon
46
Johnson & Johnson
JNJ
$635B
– –
-31,704
Closed -$5.18M
MRVI icon
47
Maravai LifeSciences
MRVI
$997M
– –
-8,540
Closed -$218K
OMCL icon
48
Omnicell
OMCL
$1.86B
– –
-30,700
Closed -$2.67M
PRQR icon
49
ProQR Therapeutics
PRQR
$243M
– –
-1,716,290
Closed -$1.28M
PRTA icon
50
CALL
Prothena Corp
PRTA
$458M
– –
-53,100
Closed -$3.22M
1
2
3

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q4 2022 Portfolio in Review

As of Q4 2022, Prosight Management held 56 positions worth $183M, down 1.8% from $187M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Prosight Management withdrew a net $8.67M in Q4 2022, closing 16 positions and reducing 7 holdings. Its most notable exit was Charles River Laboratories, an estimated $6.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier, followed by Industrials.

Against the trend, Prosight Management opened a new position in TriNet worth $5.29M.

  • Prosight Management's largest Q4 2022 buy was TriNet: 78,000 shares worth $5.29M.
  • Prosight Management added most to MeiraGTx Holdings in Q4 2022, an estimated $3.64M increase.
  • Prosight Management's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $17.7M.
  • Prosight Management fully exited Charles River Laboratories in Q4 2022, selling an estimated $6.54M.
  • Prosight Management's ten largest holdings make up 63% of its $183M portfolio in Q4 2022.
  • Prosight Management opened 18 new positions and closed 16 in Q4 2022.
  • Prosight Management's portfolio value fell 1.8% quarter-over-quarter to $183M.

Based on Prosight Management's 13F filing for Q4 2022, filed 14 Feb 2023.